移植肾功能变异性与斜率对肾移植结局的影响
该观察性研究纳入2919例移植后2年肾功能稳定的肾移植受者,分析移植后1至2年eGFR变异性(回归线周围变异系数)和斜率与长期结局的关联。结果显示eGFR变异性最高四分位与死亡风险升高相关(aHR=1.85,95%CI 1.23-2.76),但与移植肾衰竭无关;eGFR变异性与心血管事件及心血管/感染相关死亡风险升高相关,且能改善死亡预测。
要点
- eGFR变异性最高四分位者死亡风险较最低四分位升高85%(aHR=1.85)。
- eGFR变异性与移植肾衰竭风险无关(sHR=1.16,95%CI 0.85-1.58)。
- eGFR变异性与心血管事件及心血管/感染相关死亡风险升高相关。
核心结论
- eGFR变异性独立于eGFR水平和斜率,与死亡风险(尤其心血管病相关死亡)及心血管事件相关,但与移植肾衰竭无关。
- eGFR变异性可能有助于识别死亡和心血管事件高风险的肾移植受者。
研究设计与样本
- 观察性研究,纳入威斯康星同种异体移植受者数据库(WisARD)中2919例移植后2年移植肾功能稳定且移植后1至2年至少有3次门诊eGFR测量的肾移植受者。
- eGFR斜率由线性回归计算,变异性定义为围绕该回归线的变异系数。
主要发现
- 与最低四分位相比,eGFR变异性最高四分位与死亡风险升高相关(校正风险比[HR]=1.85;95%CI=1.23-2.76),独立于eGFR及其斜率。
- eGFR变异性最高四分位与移植肾衰竭风险无关(亚风险比=1.16;95%CI=0.85-1.58)。
- eGFR变异性增大与心血管相关死亡、感染相关死亡及心血管事件风险升高相关,但与恶性肿瘤相关死亡或移植物排斥无关。
- 纳入eGFR变异性显著改善死亡预测,但未改善移植肾衰竭预测。
临床怎么用
- 在肾移植受者随访中,可关注eGFR的变异性(而不仅是平均水平或斜率),以辅助识别死亡和心血管事件高风险者。
- 对eGFR变异性高的受者,可加强心血管风险因素监测与干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: It is critical to identify kidney transplant recipients (KTRs) at higher risk for adverse outcomes, to focus on monitoring and interventions to improve outcomes. We examined the associations between graft function variability and long-term outcomes in KTRs in an observational study. METHODS: We identified 2919 KTRs in the Wisconsin Allograft Recipient Database (WisARD) who had a functioning allograft 2 years posttransplantation and at least 3 outpatient measurements of estimated glomerular filtration rate (eGFR) from 1 to 2 years posttransplantation. Graft function slope was calculated from a linear regression of eGFR, and variability was defined as the coefficient of variation around this regression line. Associations of eGFR variability and slope with death, graft failure, cardiovascular events, and acute rejection were estimated. RESULTS: Compared to the lowest quartile, the highest quartile of eGFR variability was associated with a higher risk of death (adjusted hazard ratio [HR] = 1.85; 95% CI = 1.23-2.76), but not with a higher risk of graft failure (subhazard ratio = 1.16; 95% CI = 0.85-1.58), independent of eGFR and slope of eGFR. Greater eGFR variability was associated with higher risk of cardiovascular- and infection-related death and cardiovascular events but not malignancy-related death or allograft rejection. Including variability of eGFR significantly improved prediction of mortality but not prediction of graft failure. CONCLUSION: Variability of eGFR is independently associated with risk of death, especially cardiovascular disease-related death and cardiovascular events, but not graft failure. Variability of eGFR may help identify KTRs at higher risk for death and cardiovascular events.
引用
- Lyu B, Mandelbrot DA, Djamali A, et al. Graft Function Variability and Slope and Kidney Transplantation Outcomes. Kidney Int Rep. 2021. PMID: 34169205. doi:10.1016/j.ekir.2021.03.880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。